Contact: Vicki Cohn, (914) 740-2156, firstname.lastname@example.org
New Cranial Neural Crest Cell Line Developed
New Rochelle, NY, September 19, 2012-- Researchers have successfully developed a stable population of neural crest cells derived from mice that can be grown in large quantities in the laboratory and that demonstrates the potential to develop into many different cell types needed throughout the body. This powerful new research tool for understanding stem cell biology and human development and disease is described in an article published in Stem Cells and Development, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Stem Cells and Development website.
Mamoru Ishii and colleagues from University of Southern California, Los Angeles, and California Institute of Technology, Pasadena, CA, present their work leading to the development of two neural crest cell lines with stem cell characteristics in the article “A Stable Cranial Neural Crest Cell Line from Mouse.” The 09-1 cell line is capable of differentiating into four main cell types: bone, muscle, brain, and cartilage/connective tissue.
“This exciting report is the first to characterize cranial neural crest cell lines isolated from the mouse embryo, which definitively demonstrate multipotency and long-term propagation,” says Editor-in-Chief Graham C. Parker, PhD, research professor, Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine.
About the Journal
Stem Cells and Development is an authoritative peer-reviewed journal that will increase its frequency to 24 times per year beginning in 2013, both print and online. The Journal is dedicated to communication and objective analysis of developments in the biology, characteristics, and therapeutic utility of stem cells, especially those of the hematopoietic system. Complete tables of content and a free sample issue may be viewed online at the Stem Cells and Development website.
About the Publisher
Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cellular Reprogramming, Tissue Engineering, and Human Gene Therapy. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc. website.